Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Entinostat - Syndax Pharmaceuticals

Drug Profile

Entinostat - Syndax Pharmaceuticals

Alternative Names: EDP-103; Entinostat; EOC 103; KHK-2375; MS-27-275; MS-275; SND 275; SNDX-275

Latest Information Update: 05 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nihon Schering; Pfizer; University of Tokyo
  • Developer Bristol-Myers Squibb; Columbia University; Eddingpharm; Genentech; Hoosier Cancer Research Network; Indiana University; Kyowa Kirin; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (USA); Pfizer; Syndax Pharmaceuticals; UNC Lineberger Comprehensive Cancer Center
  • Class Aniline compounds; Antineoplastics; Benzamides; Carbamates; Pyridines; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Bladder cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Follicular lymphoma; Hodgkin's disease; Leukaemia; Malignant melanoma; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Uveal melanoma
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • No development reported Solid tumours

Most Recent Events

  • 23 Sep 2021 National Cancer Institute plans a phase I/II trial for Solid tumors and lymphomas (Late stage disease, Metastatic disease, Combination therapy) in USA (PO) in March 2022 (NCT05053971)
  • 23 Sep 2021 Biomarkers information updated
  • 13 Jul 2021 Ventana Medical Systems is now called Roche Tissue Diagnostics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top